Novavax, COVID and mRNA vaccine
Novavax Inc. closed $10.57 below its 52-week high ($23.86), which the company reached on June 6th.
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
Novavax’s vaccine is based on protein technology, which takes longer to manufacture than mRNA vaccines like those made by Pfizer and BioNTech and Moderna. Protein-based vaccines work by getting ...
“We may surprise people with where we’re headed,” the chief exec says. John Jacobs wasn’t interested when a recruiter approached him about the Novavax Inc. CEO job in 2022. Jacobs was head ...
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Ruxandra Draghia-Akli, MD, PhD, will join the Company in ...
Novavax Inc. closed $11.06 below its 52-week high ($23.86), which the company achieved on June 6th.
Zacks.com on MSN4d
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should KnowNovavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...
John Jacobs left Plymouth Meeting's Harmony Biosciences in 2023 after overseeing its IPO. Now, he's got another biotech firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback